Clinical Trial Update: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating adding omarigliptin (MK-3102) to patients with type 2 diabetes mellitus inadequately controlled on glimepiride and metformin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• MK-3102
• Omarigliptin (omarigliptin)
• metformin (metformin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2015-11-25